PHARMERICA CORPORATION (NYSE: PMC) upgraded to Buy with price target $40 by UBS
UBS upgraded PHARMERICA CORPORATION (NYSE: PMC) to Buy with price target $40. Previously UBS rated Neutral
with price target $13 PHARMERICA CORPORATION (NYSE: PMC) on 04/25/2012, when the stock price was $11.88. Since then, PHARMERICA CORPORATION's stock price has gained 201% as of 08/10/2015's recent price of $35.76.
PharMerica Corporation is an institutional pharmacy services company. The Company services healthcare facilities and provides management pharmacy services to hospitals. It operates more than 100 institutional pharmacies in 40 states. The Company also provides pharmacy management services to 84 hospitals in the United States. The Company operates in two business segments: institutional pharmacies, which provides pharmacy services to nursing centers and other healthcare providers, and the hospital pharmacy management business, which provides management services to Kindred Healthcare, Inc.?s (Kindred) hospitals. On July 9, 2008, the Company purchased the 49% minority interest held by a third-party in its joint ventures. On November 1, 2008, the Company acquired an institutional pharmacy business providing medications, pharmacy and medical supplies and services to residents of skilled nursing homes.
is the leading global wealth manager, a top tier investment banking and securities firm, and one of the largest global asset managers.
In Switzerland, UBS
is the market leader in retail and commercial banking.
With headquarters in Zurich and Basel, Switzerland, UBS
operates in over 50 countries and from all major international centers.
employs more than 80,000 people.